SCHEMBL2368702

SCHEMBL2368702

CNC(=O)Cc1nc(NCc2cccc(C)n2)c2c(-c3ccc(F)cc3)csc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SIRT5 Q9NXA8 1/20 0.39
ESR1 P03372 4/20 0.37
TGM2 P21980 2/20 0.37
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
TNF P01375 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368176 0.92 LMNA (0.47) LMNAALDH1A1SMN1; SMN2KDM4ERXFP1
SCHEMBL2369471 0.88 ALDH1A1 (0.47) LMNAALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL2368394 0.88 TNF (0.51) LMNAALDH1A1SMN1; SMN2KDM4EESR1
SCHEMBL2368714 0.86 ESR1 (0.40) LMNAALDH1A1SMN1; SMN2HPGDRXFP1
SCHEMBL3382770 0.85 ALDH1A1 (0.41) LMNAALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL2368616 0.84 MEN1 (0.42) LMNAALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL3384963 0.81 ESR1 (0.57) LMNAALDH1A1SMN1; SMN2HPGDRXFP1
SCHEMBL2368488 0.80 TNF (0.59) LMNAALDH1A1SMN1; SMN2ESR1HTT
SCHEMBL2368659 0.80 ESR1 (0.39) LMNAALDH1A1HPGDRXFP1SIRT5
SCHEMBL2368960 0.80 ESR1 (0.39) LMNAALDH1A1SMN1; SMN2HPGDRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885ALDH1A1 247/4885SMN1; SMN2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.